Becart
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down ~22% since market close on July 18 and the reason could be that the company has several early-stage candidates in partnership with recently belaguered Sarepta Therapeutics (NASDAQ:SRPT).
- Arrowhead closed July 19 down ~11% and is